This review discusses the controversial pathogenesis and suggested mechanisms of ACE-I-induced chronic cough, a side effect causing discontinuation in one out of five patients.
This review discusses the controversial mechanisms underlying ACE inhibitor-induced chronic cough, a side effect leading to discontinuation in 20% of patients.
Angiotensin-converting enzyme inhibitors (ACE-I) are widely used in diseases, such as hypertension, congestive heart failure, and myocardial infarction. Although these drugs are well tolerated, one out of five patients discontinues ACE-I due to drug side effects, mainly chronic cough. However, the pathogenesis of ACE-I-induced cough remains controversial and requires further study. In this review, the mechanisms that are suggested in ACE-I-induced cough pathophysiology will be discussed in detail in light of the current literature.
İnsu Yılmaz (Tue,) conducted a review in ACE-I-induced cough. Angiotensin-converting enzyme inhibitors (ACE-I) was evaluated. This review discusses the controversial pathogenesis and suggested mechanisms of ACE-I-induced chronic cough, a side effect causing discontinuation in one out of five patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: